ATOM is the only B2B stem cell supplier offering a 100% concentrated MUSE stem cell product for doctors, clinics, and medical practices — alongside ecosystem-preserved IV and Injection products. FDA-registered lab. Physician training and compliance documentation included.
Written for licensed medical providers. Content reviewed against published peer-reviewed research including PubMed-indexed Phase 1 and Phase 2 clinical trial data on MUSE cell therapy (Japan, 2018–2024). All referenced trials are publicly available. ATOM Stem Cells is a B2B product supplier, not a pharmaceutical manufacturer, and does not claim FDA approval for any indication.
MUSE stands for Multilineage-Differentiating Stress-Enduring. They are a rare subpopulation of mesenchymal stem cells (MSCs) found naturally in umbilical cord Wharton's Jelly tissue at roughly 1–2% of the MSC population. Physicians are purchasing MUSE stem cell products because they carry biological capabilities that standard MSC-only products cannot replicate.
MUSE cells represent roughly 1–2% of MSCs in cord tissue. Producing a 100% concentrated MUSE stem cell product — available for direct physician purchase — requires processing significantly more umbilical cord tissue per vial and applying precision isolation that specifically preserves MUSE cells rather than maximizing total MSC count. Most suppliers optimize for cell count metrics because they're easier to market. Atom MUSE is produced for physicians who understand that cell type matters more than cell volume. That's why no comparable wholesale MUSE stem cell product currently exists in the US market — view Atom MUSE on the product page.
Atom IV and Atom Injection preserve MUSE cells naturally as part of the full Wharton's Jelly ecosystem at less than 5% of total cell population. Atom MUSE is 100% processed MUSE stem cells — the first dedicated MUSE stem cell product available for wholesale purchase by licensed doctors and clinics in the US. View current pricing →
Full Wharton's Jelly ecosystem for IV infusion. MUSE cells naturally present at less than 5% of total cell population alongside conventional MSCs, stromal cells, and extracellular matrix. Best for systemic protocols, anti-aging, autoimmune, and whole-body inflammation management.
Full Wharton's Jelly ecosystem for direct tissue injection. MUSE cells naturally present at less than 5%. Optimal for orthopedic, joint, and spinal protocols — concentrates the full cellular ecosystem, including MUSE cells, directly at the target site.
MUSE cells are naturally present at roughly 1–2% of the MSC population in umbilical cord tissue. Producing a 100% MUSE cell product for physician purchase means processing substantially more cord material per vial — and applying a precision isolation protocol that preserves functional MUSE cells specifically. Atom MUSE's wholesale price reflects actual input costs, not a margin decision. For physicians treating complex neurological recovery, post-cardiac patients, or cases that haven't responded adequately to standard MSC protocols, the clinical rationale is clear. Current pricing is published on the ATOM product page.
These four biological properties distinguish MUSE cells from standard MSC products — and justify Atom MUSE as a premium-priced purchase for practices treating complex cases.
MUSE cells express the S1PR2 receptor, enabling them to detect sphingosine-1-phosphate (S1P) released by damaged tissue and navigate toward it after IV infusion. Published Phase 2 trials documented MUSE cells homing to stroke-injured brain and infarcted cardiac tissue via simple IV drip — without direct organ injection. Standard MSCs do not reliably demonstrate this behavior. For IV-protocol practices buying MUSE stem cell products, this is the most clinically significant differentiator.
Phase 2 IV trial documentedStandard MSC products work primarily through paracrine signaling — anti-inflammatory cytokines and growth factor release. MUSE cells go further: engrafting into damaged tissue, consuming cellular debris via phagocytosis, and potentially regenerating functionally appropriate replacement cells. This shifts the therapeutic mechanism from signaling-only to structural tissue repair — relevant for providers treating neurological, cardiac, or complex degenerative conditions where paracrine effects alone are insufficient.
Ectoderm / mesoderm / endodermMUSE cells express very low levels of HLA antigens. The immune system does not identify them as foreign. Across multiple Phase 2 trials, patients received allogeneic donor MUSE cells without immunosuppressant medications and without rejection events. For clinics and medical practices purchasing MUSE stem cell products, this simplifies treatment protocols — no medication coordination, reduced patient burden, full allogeneic efficacy from a straightforward IV or injection procedure.
No immunosuppressants in Phase 2iPSCs and embryonic stem cells carry tumor risk via c-Myc. MUSE cells express OCT4, SOX2, and NANOG (broad differentiation capability markers) without dangerous c-Myc levels. Published Phase 2 safety data across multiple trials has identified zero tumor formation in any subject. This is the safety profile that makes MUSE stem cell products viable for clinical purchase and use where more powerful pluripotent cells are not — and the reason Atom MUSE can be offered to licensed providers as a wholesale product.
Zero tumor events — Phase 2 data| Property | Standard MSC Products (market) | Atom MUSE — Buy 100% MUSE Stem Cells |
|---|---|---|
| Tumor risk | Low — no teratoma, limited differentiation | ✓ Non-tumorigenic pluripotency — zero events in Phase 2 |
| Differentiation capability | Primarily mesoderm lineage | ✓ All three germ layers (ectoderm, mesoderm, endoderm) |
| Active injury homing | Inconsistent, passive | ✓ Active via S1PR2 — confirmed in Phase 2 IV trials |
| Tissue engraftment | Rare; primarily paracrine effect | ✓ Structural engraftment documented in cardiac and neural trials |
| Immune rejection risk | Moderate — phagocytized over time | ✓ Low HLA — no immunosuppressants required in any published trial |
| Survival in hostile tissue | 95%+ may die within 24 hrs post-injection | ✓ Stress-enduring — survives the hostile environments your patients present |
| Available to purchase wholesale | No MUSE-specific B2B product exists elsewhere | ✓ Atom MUSE — available to licensed providers now via atomstemcells.com/products |
Atom MUSE delivers maximum MUSE cell concentration. It performs best stacked on top of Atom IV or Injection — which supply the full cellular ecosystem those MUSE cells need to function as designed.
Pluripotent differentiation, active injury homing, tissue integration, stress endurance. Available concentrated at 100% in Atom MUSE for maximum delivery.
Broad immune modulation, paracrine signaling, cytokine regulation. The biological context that gives MUSE cells the signaling environment to function optimally.
Structural scaffolding, vascular support, microenvironmental balance — all preserved in full ecosystem ATOM products alongside natural MUSE cell content.
The native signaling scaffold that contextualizes cellular behavior. Present in Wharton's Jelly products. Lost in aggressive isolation protocols.
Purchasing Atom MUSE for concentrated MUSE cell delivery is the clinical decision for complex cases. Pairing it with Atom IV or Injection is the protocol decision for optimal results. Both are available from a single wholesale supplier.
Risks that increase when MUSE cells operate without companion MSC ecosystem support.
Amplified inflammatory response. Companion MSCs buffer T-cell activation and macrophage polarization. Without them, cytokine release can be amplified rather than modulated — counterproductive for inflammatory conditions.
Microvascular trapping risk. Isolated cell products are more prone to lodging in pulmonary or hepatic microvasculature. Stromal companions normally buffer this risk during circulation.
Dysregulated differentiation. Without ECM signals and paracrine cues, MUSE cells lack the contextual instruction set determining differentiation direction. Outcomes become less predictable.
Higher outcome variability. Single-cell-type protocols show greater patient-to-patient variability than stacked full-ecosystem approaches — an operational liability for systematized clinic protocols.
Published Phase 1 and Phase 2 human trials — not animal models. When patients ask why their doctor is purchasing and using MUSE stem cell products, these are the studies that support the clinical rationale.
MUSE cells administered via systemic IV following ischemic stroke. Cells homed to brain tissue via S1PR2 without direct neural injection. Primary endpoint: activities of daily living (ADL) improvement at follow-up.
Single IV infusion post-acute MI. MUSE cells homed to cardiac tissue. Left ventricular ejection fraction (LVEF) and regional wall motion evaluated vs. placebo group over 3 months.
Monthly IV MUSE infusions in ALS patients over 6-month protocol evaluating safety, tolerability, and early efficacy signals. Phase 2 in active planning based on confirmed safety profile.
MUSE cells in neonates with brain injury from oxygen deprivation — the most vulnerable possible patient population. Evaluated safety and neurodevelopmental outcomes over 18-month follow-up period.
These are Phase 1 and Phase 2 trials — not FDA-approved indications. MUSE stem cell therapy for doctors is administered under the FDA's framework for minimally manipulated, homologously used cell products. Phase 3 trials for acute MI are in planning. ATOM provides practitioners with accurate patient education materials framing the evidence correctly. All source trials are publicly indexed on PubMed and ClinicalTrials.gov.
Exosomes are subcellular signaling particles: microRNA, proteins, and lipids carrying biological instructions to surrounding tissue. If cells are the workers, exosomes are the instructions they send.
MUSE-derived exosomes carry signals reflecting the biology of a cell defined by surviving stress. Research has found their secretome enriched with factors involved in stemness regulation, apoptosis control, immune modulation, oxidative stress response, and ECM remodeling — precisely the signals relevant to the inflamed environments your patients present.
For physicians purchasing MUSE stem cell products to treat chronic inflammation, neurodegeneration, or oxidative-stress-driven pathology — the exosomal signaling profile of MUSE cells is a clinically meaningful additional layer over generic MSC exosome products.
MUSE exosome research is early-stage. Both exosome profiles are present naturally in ATOM products — no separate purchase or add-on required.
Both layers are naturally present in all ATOM products. No separate SKU or additional purchase required.
Buy MUSE stem cells for your practice direct from ATOM — the only supplier offering a concentrated MUSE product at wholesale physician pricing. Compliance documentation, physician training, and done-for-you marketing support included with every partner account.
Product. Marketing. Training. Everything you need — nothing you don't.